NCT06223542View on ClinicalTrials.gov

Studying TAK-243 in Patients With Advanced Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

March 24, 2025

Primary Completion Date

April 15, 2026

Study Completion Date

April 15, 2026

Conditions
Advanced LymphomaAdvanced Malignant Solid NeoplasmIndolent Non-Hodgkin LymphomaMetastatic Malignant Solid NeoplasmRecurrent Malignant Solid NeoplasmRefractory Malignant Solid Neoplasm
Interventions
PROCEDURE

Biopsy Procedure

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo collection of blood

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Echocardiography Test

Undergo ECHO

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

DRUG

UAE Inhibitor TAK-243

Given IV

Trial Locations (1)

20892

RECRUITING

National Cancer Institute Developmental Therapeutics Clinic, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH